Correction to Gilead Sciences Article
03 May 2019 - 1:42PM
Dow Jones News
Analysts had projected Yescarta sales of $98.5 million. "Gilead
Sciences Reports Q1 Results Above Wall Street Targets," at 2109
GMT, misstated that they had projected sales of $98.5 billion in
the eighth paragraph.
(END) Dow Jones Newswires
May 02, 2019 23:27 ET (03:27 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2024 to May 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From May 2023 to May 2024